Meeting NewsVideo

VIDEO: Expert calls attention to barriers to PCSK9 inhibitor access

SANTA ANA PUEBLO, N.M. — In this video, Seth J. Baum, MD, FASPC, discusses current challenges in access to PCSK9 inhibitors and how to surmount these barriers.

Barriers to PCSK9 inhibitor access are “extraordinarily problematic,” according to Baum, who is immediate past president of the American Society for Preventive Cardiology, chief medical officer of Excel Medical Clinical Trials and clinical affiliate professor of biomedical science at Florida Atlantic University in Boca Raton.

Baum highlights strategies to improve patient access to PCSK9 inhibitors, such as use of the ASPC app, which features a 10-step approach, single-page prior authorization and appeal letters, case studies, references to key papers, links to advocacy sites, information on specialty pharmacies and other resources.

Watch the video for more.

SANTA ANA PUEBLO, N.M. — In this video, Seth J. Baum, MD, FASPC, discusses current challenges in access to PCSK9 inhibitors and how to surmount these barriers.

Barriers to PCSK9 inhibitor access are “extraordinarily problematic,” according to Baum, who is immediate past president of the American Society for Preventive Cardiology, chief medical officer of Excel Medical Clinical Trials and clinical affiliate professor of biomedical science at Florida Atlantic University in Boca Raton.

Baum highlights strategies to improve patient access to PCSK9 inhibitors, such as use of the ASPC app, which features a 10-step approach, single-page prior authorization and appeal letters, case studies, references to key papers, links to advocacy sites, information on specialty pharmacies and other resources.

Watch the video for more.

    See more from American Society for Preventive Cardiology Congress on CVD Prevention